Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research[1][2].
Product Specifications
CAS Number
3024821-77-7
UNSPSC
12352100
Target
VEGFR
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
References & Citations
[1]Internacionales D C. International Nonproprietary Names for Pharmaceutical Substances (INN) [J]. WHO Drug Information, 2025, 39 (2) .|[2]Wang X, et al. Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. Front Cell Dev Biol. 2020 Nov 16;8:599281.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
VEGFR2/KDR/Flk-1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040226-500 1x 500 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
